Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwai.
Pridmore, MD, FRANZCP, Senior Professor, Discipline of Psychiatry, University of Tasmania, Hobart, Tasmania, Australia and TMS Unit, Saint Helens Private Hospital, Hobart, Tasmania.
Psychopharmacol Bull. 2023 Feb 28;53(1):55-57.
No single neurotransmitter aberration could explain the heterogeneity of schizophrenia syndrome and thus, treatment strategies capitalizing solely on a single neurotransmitter system (e.g., DA blockade) is less likely to be fully successful on clinical grounds. Hence, there is a pressing need to develop antipsychotics above and beyond DA antagonism. In this regard, authors brief on agents that sound pretty promising and might usher in a new sparkle in the psychopharmacotherapy of schizophrenia. This paper is a sequel for authors' previous article on future of schizophrenia psychopharmacotherapy.
没有单一的神经递质异常可以解释精神分裂症综合征的异质性，因此，仅基于单一神经递质系统（例如，DA 阻断）的治疗策略在临床上不太可能完全成功。因此，迫切需要开发超越 DA 拮抗作用的抗精神病药物。在这方面，作者简要介绍了一些听起来很有前途的药物，这些药物可能会为精神分裂症的精神药理学治疗带来新的希望。本文是作者之前关于精神分裂症精神药理学治疗未来的文章的续篇。
